Zhou Xufeng, Jin Xiulin, Yang Linhong, Wei Xiaoli
Department of Otorhinolaryngology, The First Affiliated Hospital of Jiamusi University, Jiamusi, China.
Ann Transl Med. 2022 Feb;10(3):142. doi: 10.21037/atm-22-237.
Secretory otitis media is a very common nonsuppurative inflammatory disease in otorhinolaryngology. Ambroxol hydrochloride helps to improve ciliary movement in the ear canal and promote the dissolution and discharge of secretions. However, its effect still lacks systematic evaluation. We conducted a meta-analysis of clinical studies to systematically evaluate the application effect of ambroxol hydrochloride.
A computer-based search of the Chinese Biomedical Database (CBM), China National Knowledge Infrastructure (CNKI), PubMed, and Web of Science databases was conducted using the keywords "Ambroxol hydrochloride" & "secretory otitis media". Randomized controlled trials published after 2015 were selected and then screened and analyzed using RevMan 5.4 software.
Ten studies involving a total of 998 patients were included. Meta-analysis showed that adding ambroxol hydrochloride to the original glucocorticoid treatment improved therapeutic efficacy [odds ratio (OR) =4.95, 95% confidence interval (CI): 3.27, 7.50, P<0.00001], reduced tympanic pressure after treatment [mean difference (MD) =-19.04, 95% CI: -22.72, -15.36, P<0.00001], and increased the pure tone threshold (MD =6.37, 95% CI: 5.36, 7.37, P<0.00001), without increasing adverse reactions (OR =0.51, 95% CI: 0.14, 1.85, P=0.30).
On the basis of the original treatment of secretory otitis media, adding ambroxol hydrochloride treatment improved the therapeutic effect, reduced tympanic pressure after treatment, and improved the pure tone threshold (hearing), without increasing adverse reactions.
分泌性中耳炎是耳鼻咽喉科一种非常常见的非化脓性炎症性疾病。盐酸氨溴索有助于改善耳道内纤毛运动，促进分泌物的溶解和排出。然而，其效果仍缺乏系统评价。我们进行了一项临床研究的荟萃分析，以系统评价盐酸氨溴索的应用效果。
使用关键词“盐酸氨溴索”和“分泌性中耳炎”，对中国生物医学文献数据库（CBM）、中国知网（CNKI）、PubMed和Web of Science数据库进行计算机检索。选取2015年后发表的随机对照试验，然后使用RevMan 5.4软件进行筛选和分析。
纳入10项研究，共998例患者。荟萃分析表明，在原糖皮质激素治疗基础上加用盐酸氨溴索可提高治疗效果[比值比（OR）=4.95，95%置信区间（CI）：3.27，7.50，P<0.00001]，降低治疗后的鼓室压[平均差（MD）=-19.04，95%CI：-22.72，-15.36，P<0.00001]，并提高纯音听阈（MD =6.37，95%CI：5.36，7.37，P<0.00001），且不增加不良反应（OR =0.51，95%CI：0.14，1.85，P=0.30）。
在分泌性中耳炎原治疗基础上，加用盐酸氨溴索治疗可提高治疗效果，降低治疗后的鼓室压，改善纯音听阈（听力），且不增加不良反应。
